Verrica partner launches YCANTH molluscum treatment in Japan Feb 9, 2026 08:03AM
TD Cowen on Verrica Pharmaceuticals (VRCA): 'We are encouraged by the increased Ycanth prescribing in lieu of compounded cantharidin' Jan 7, 2026 11:34AM
Brookline Capital Markets Upgrades Verrica Pharmaceuticals (VRCA) to Buy Dec 18, 2025 03:41AM
Verrica Pharmaceuticals Inc. (VRCA) files for 14.76M share offering by selling stockholders Dec 15, 2025 04:18PM
Verrica Pharmaceuticals Inc. (VRCA) Tops Q3 EPS by 21c Nov 14, 2025 05:41PM


Nov 5, 2025 06:36AM Lucid Capital Markets Starts Verrica Pharmaceuticals (VRCA) at Buy
Oct 20, 2025 04:06PM Verrica gets EMA backing for YCANTH approval path in Europe
Sep 19, 2025 08:02AM Verrica receives $10 million from Japan approval of molluscum treatment
Aug 13, 2025 10:27AM Verrica Pharmaceuticals (VRCA) PT Raised to $20 at TD Cowen
Aug 12, 2025 04:02PM Verrica Pharmaceuticals Inc. (VRCA) Tops Q2 EPS by 11c
Jul 9, 2025 07:02AM Verrica reports 32.8% quarterly growth in YCANTH applicator units
Jul 1, 2025 07:00AM Verrica Pharmaceuticals (VRCA) Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment
May 13, 2025 06:31PM Verrica Pharmaceuticals Inc. (VRCA) Tops Q1 EPS by 3c
Apr 8, 2025 06:46AM H.C. Wainwright Reiterates Neutral Rating on Verrica Pharmaceuticals (VRCA)
Apr 2, 2025 04:07PM Verrica Pharmaceuticals Inc. (VRCA) named Gavin Corcoran MD to board
Mar 26, 2025 07:02AM Verrica Pharmaceuticals Inc. (VRCA) Appoints Noah L. Rosenberg as Chief Medical Officer
Mar 11, 2025 05:09PM Verrica Pharmaceuticals Inc. (VRCA) Files $150M Mixed Shelf
Mar 11, 2025 04:36PM Verrica Pharmaceuticals Inc. (VRCA) Tops Q4 EPS by 6c
Jan 21, 2025 07:02AM Verrica (VRCA) Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Confer
Jan 6, 2025 03:50PM Verrica Pharmaceuticals (VRCA) PT Lowered to $3 at Jefferies
Dec 20, 2024 07:01AM Verrica Pharmaceuticals Inc. (VRCA) Provides Business and Operational Update
Dec 6, 2024 08:01AM Verrica Pharmaceuticals (VRCA) Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
Nov 21, 2024 07:31AM Verrica Pharmaceuticals Inc. (VRCA) Announces Pricing of $42.0 Million Public Offering
Nov 20, 2024 04:07PM Verrica Pharmaceuticals Inc. (VRCA) Announces Proposed Share Offering
Nov 4, 2024 07:17PM Verrica Pharmaceuticals Inc. (VRCA) Misses Q3 EPS by 5c
Oct 21, 2024 08:46AM Verrica Pharmaceuticals (VRCA) PT Lowered to $10 at TD Cowen
Oct 3, 2024 05:35AM Needham Downgrades Verrica Pharmaceuticals (VRCA) to Hold
Oct 2, 2024 07:32AM Verrica Pharmaceuticals (VRCA) Announces Restructuring of Commercial Organization
Aug 15, 2024 06:16AM Verrica Pharmaceuticals (VRCA) PT Lowered to $13 at RBC Capital
Aug 14, 2024 07:46AM Verrica Pharmaceuticals Inc. (VRCA) Tops Q2 EPS by 4c
Aug 14, 2024 07:30AM Verrica Pharmaceuticals (VRCA) Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315
Jul 1, 2024 07:31AM Verrica Pharmaceuticals (VRCA) Announces Litigation Settlement with Dormer Laboratories, Inc.